Archive: Company News
Company News: Curetis, Beijing Clear Biotech Expand Strategic Collaboration for Unyvero in Greater China
— Exclusive Unyvero A50 distribution agreement extended to eight years
— Significant further contractual minimum purchase commitments by Beijing Clear Biotech for additional contract years
— Good progress in regulatory process for gaining market access for Unyvero A50 in China
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has significantly expanded its strategic collaboration with Beijing Clear Biotech (BCB) for the exclusive distribution of the Unyvero A50 Platform and Unyvero A50 Application Cartridges in Greater China.
Company News: Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
— Funding enables further acceleration of commercial expansion and R&D programs
— EUR 3.5 million of first tranche of EUR 5 million to be funded today
This announcement contains inside information within the meaning of Article 7(1) of the Market Abuse Regulation.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has secured up to EUR 20 million in growth capital through the issuance of convertible notes by Curetis N.V. with share subscription warrants, to YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, a U.S.-based management firm (the “Investor” or “Yorkville”). Read more…
Company News: Curetis Publishes Interim Report for the First Half-Year 2018
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that further to its Half-Year Results Announcement made on 14 August 2018 it has filed its interim report for the first half year of 2018, including the half-year financial statements prepared in accordance with IAS 34 “Interim Financial Reporting, (the “Interim Statements”) with the Autoriteit Financiële Markten (the “AFM”) in the Netherlands today.
Company News: ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 plus Nivolumab in JAMA Oncology
ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2 combination trial with ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody and PD-1 checkpoint inhibitor (NCT02426892). The open-label trial in patients with HPV-16 associated cancers demonstrated safety and efficacy, resulting in an improved survival as compared to historical nivolumab monotherapy results.